Quantum Genomics, an innovative biopharmaceutical company developing new therapies for cardiovascular diseases (Alternext - FR0011648971 - ALQGC), announces the appointment of Marc Karako and Jean-Philippe Milon, respectively CFO and COO. They will strengthen the management team of Quantum Genomics, supporting Lionel Ségard, Chairman and CEO, and Fabrice Balavoine, Vice President Research & Development.
Marc Karako has a long experience as CFO of multinational companies. In particular, he was Executive Vice President and group CFO of Carlson Wagonlit Travel, group Chief Financial and Legal Officer of Vallourec and Vice President Finance at Thomson. From 1985 to 1995, he held various financial management positions at IBM Europe.
Marc Karako holds a Master of Science from Ecole des Ponts ParisTech and an MBA from the University of Chicago.
Also a Board member of the Company, he will be more particularly in charge of financings, legal, investor relations and the financial communication of Quantum Genomics.
Dr. Jean-Philippe Milon held various management positions at local and international level at Bayer where he notably was involved in primary care and cardiology. He is thus one of the drug experts in high blood pressure and associated pathologies. He also managed the cardiovascular franchise of Sandoz. He then joined the Executive Committee of Bayer to lead the global operations of mergers and acquisitions, licensing and business development.
Jean-Philippe Milon has a PHD in Pharmacy and earned an MBA at ESCP Europe.
His responsibilities include the business development strategy of Quantum Genomics whose objective is to conclude, during phase 2, a partnership agreement with a pharmaceutical company regarding QGC001, its first in class drug candidate for the treatment of hypertension.
He will also work in close collaboration with the VP of R&D and the Medical Director (to be hired) in order to optimize the products development plan.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical research company developing new therapies for unmet medical needs in the field of cardiovascular diseases, including hypertension and heart failure.
Quantum Genomics is in the process of developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics will be listed from 10 April, 2014 on the Alternext market in Paris (ISIN code: FR0011648971 – Ticker symbol: ALQGC).
Chief Executive Officer
(+33) 1 60 13 76 80
Chief Financial Officer – Investor relations
(+33) 1 60 13 76 84
(+33) 1 53 67 07 80
- SECURITY MASTER Key: ymlqksdvZGednZpvapiYmGmWaG9il2jHa2Wdl2RwmJ6ba26RlWmVb5zLZmxmnmtn
- Check this key: https://www.security-master-key.com.
Powered by Actusnews Wire (press release services) ©